drugset
drugset / Trial / NCT03203642

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

NCT03203642 ↗

Phase 2 Completed 80 enrolled Kadmon, a Sanofi Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of the study was to compare and evaluate safety and efficacy of tesevatinib 50 milligrams (mg) versus placebo in participants with autosomal dominant polycystic kidney disease (ADPKD).

Timeline

Start
2017-10-12
Primary completion
2022-01-25
Completion
2022-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Tesevatinib Small molecule 50 mg Oral

Indications

autosomal dominant polycystic kidney disease